PubMed Health⌕ Search

PubMed · 1768012

Linear systems dynamics in toxicokinetic studies.

Abstract

Linear systems dynamics are introduced to study kinetics particularly in experimental exposure to toxic agents and to extrapolate the experimental results to the field of occupational exposure. The relationship between the agent input (e.g. dose, external exposure) and the concentration-time curve [C(t)] in biological media plays a central part. When this relationship has been established the C(t) can be predicted or the dose as function of time can be estimated retrospectively on an individual basis. Linear systems dynamics offer a kinetic model-independent approach which means that no assumptions are required about compartments, bloodflows, partition coefficients, etc. The systems dynamics appear to be a powerful tool to predict the time courses of an agent or toxic metabolites in, for example, blood or a target organ on the basis of a short-term experimental exposure. The power of systems dynamics becomes obvious especially in the case of non-constant rates of inputs (dose) into systemic blood at, for example, dermal exposure. Also the systems approach appears to be suitable to determine the metabolic rate of entrance into the system blood as function of the parent agent or a second agent. The paper emphasizes the value of human exposure experiments under controlled conditions in order to verify the outcomes of physiologically based simulation models and to provide experimental data for these models.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J J Opdam. 1991. Linear systems dynamics in toxicokinetic studies.. https://doi.org/10.1093/annhyg%2F35.6.633

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Curvature-adjusted optimal design of sampling times for the inference of pharmacokinetic compartment models.

In pharmacokinetics, compartment models are often used to describe the time course of blood concentration after the administration of a drug. In this article, we propose an optimal design criterion for precise estimation of parameters included in the compartment model and illustrate the non-sequential design of sampling times of blood drug concentration data in individual pharmacokinetics. The proposed optimal design criterion minimizes the determinant of the mean-squared error matrix of the parameter estimator that is quadratically approximated by the curvature array. Therefore, the proposed criterion considers the intrinsic and parameter-effects nonlinearity underlying the compartment model, and so is applicable in a pharmacokinetic experiment where the sample size of the blood drug concentration data is quite small.

Biological Availability↗

Biowaiver monographs for immediate release solid oral dosage forms: isoniazid.

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing isoniazid as the only active pharmaceutical ingredient (API) are reviewed. Isoniazid's solubility and permeability characteristics according to the Biopharmaceutics Classification System (BCS), as well as its therapeutic use and therapeutic index, its pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. Isoniazid is "highly soluble" but data on its oral absorption and permeability are inconclusive, suggesting this API to be on the borderline of BCS Class I and III. For a number of excipients, an interaction with the permeability is extreme unlikely, but lactose and other deoxidizing saccharides can form condensation products with isoniazid, which may be less permeable than the free API. A biowaiver is recommended for IR solid oral drug products containing isoniazid as the sole API, provided that the test product meets the WHO requirements for "very rapidly dissolving" and contains only the excipients commonly used in isoniazid products, as listed in this article. Lactose and/or other deoxidizing saccharides containing formulations should be subjected to an in vivo BE study.

Biological Availability↗

Experimental approaches for studying uptake and action of herbal medicines.

In order to gain wider credibility, herbal medicines must go through the rigorous scientific scrutiny to which synthetic drugs are subjected, and this includes investigating their absorption, bioavailability and metabolism. This review describes approaches for determining how active compounds in herbal formulations enter the systemic circulation. To assess how bioactive molecules enter the target organs and cells, specific cell lines and organ culture models can be used, followed by in vitro models to show how they may regulate digestion, energy balance and metabolism. This could lead to a better understanding of how herbal medicines affect digestion and absorption; fundamental questions which should be answered in addition to their mechanism of action.

Biological Availability↗